In the following analyses, patients were divided into PD‐1 (NIV/PEM) and BRAF + MEK (D + T) cohorts based on their second course of adjuvant melanoma therapy after recurrence during or after the first adjuvant treatment (RFS2). This evidence concerns the gene BRAF and melanoma.